PetVivo’s Regenerative Medicine Strategy Takes a Major Step Forward

Jun 30, 2026

👉 Watch the full interview here:

PetVivo CEO John Lai discusses the company’s acquisition of PZO Bio and how combining proprietary nanofiber technology with the SPRYNG™ platform could expand regenerative medicine applications across veterinary healthcare and future human medical markets.

Watch the full interview to learn more about PetVivo’s technology platform, product development strategy, and long-term vision for regenerative medicine.

#PetVivo #Biotechnology #RegenerativeMedicine #MedTech #HealthcareInnovation #Investing #BusinessNews #BiotechStocks #GrowthStocks #VeterinaryMedicine #LifeSciences #MedicalTechnology #Innovation #NASDAQ #Healthcare

PetVivo’s Regenerative Medicine Strategy Takes a Major Step Forward

Recommended

Stewards CEO Bilal Adam: Global Investment Strategy, Private Credit and Nasdaq Growth

BioVie CEO: Promising Phase 2 Results for Long COVID and Parkinson’s Disease

FreeCast CEO: How Its Streaming Software Platform Could Generate Multiple Revenue Streams

American Fusion Expands Texas Data Center Pipeline and Advances Texatron Testing Plans

BioVie Reports Positive Phase 2 Parkinson’s Trial Results for Bezisterim in Key Patient Subgroup

BioVie Reports Significant Long COVID Symptom Improvements in Phase 2 Clinical Trial

PetVivo’s Regenerative Medicine Strategy Takes a Major Step Forward

Recommended

Stewards CEO Bilal Adam: Global Investment Strategy, Private Credit and Nasdaq Growth

BioVie CEO: Promising Phase 2 Results for Long COVID and Parkinson’s Disease

FreeCast CEO: How Its Streaming Software Platform Could Generate Multiple Revenue Streams

American Fusion Expands Texas Data Center Pipeline and Advances Texatron Testing Plans

BioVie Reports Positive Phase 2 Parkinson’s Trial Results for Bezisterim in Key Patient Subgroup

BioVie Reports Significant Long COVID Symptom Improvements in Phase 2 Clinical Trial

Share

Investor Accreditation

For Individuals

Thank You!